# EDGAR Filing Document

**Accession Number:** 0001478831
**File Stem:** 0001478831-26-000004
**Filing Date:** 2026-1
**Character Count:** 8459
**Document Hash:** d77755951a458a3ae58548e800b440c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001478831-26-000004.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001478831-26-000004

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20160523

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stein Jeffrey
- **CENTRAL INDEX KEY:** 0001478831

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36912
- **FILM NUMBER:** 26517078

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE, SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stein Jeffrey<br><sub>(Last) (First) (Middle)</sub><br>6310 NANCY RIDGE DRIVE<br>SUITE 101<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2016-05-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Cidara Therapeutics, Inc. [ CDTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2016-05-23 |  | J<sup>(1)</sup> |  | 270<sup>(2)</sup> | D | <sup>(1)</sup> | 10025 | D |  |
| Common Stock | 2017-03-31 |  | J<sup>(3)</sup> |  | 645<sup>(2)</sup> | D | 155<sup>(2)</sup> | 9380 | D |  |
| Common Stock | 2017-03-31 |  | P<sup>(3)</sup> |  | 645<sup>(2)</sup> | A | 155<sup>(2)</sup> | 65754 | I | By trust |
| Common Stock | 2017-06-05 |  | J<sup>(4)</sup> |  | 750<sup>(2)</sup> | D | 118.948<sup>(2)</sup> | 8630 | D |  |
| Common Stock | 2017-06-05 |  | P<sup>(4)</sup> |  | 750<sup>(2)</sup> | A | 118.948<sup>(2)</sup> | 66504 | I | By trust |
| Common Stock | 2017-09-12 |  | J<sup>(5)</sup> |  | 367<sup>(2)</sup> | D | 135.80<sup>(2)</sup> | 8263 | D |  |
| Common Stock | 2017-09-12 |  | P<sup>(5)</sup> |  | 367<sup>(2)</sup> | A | 135.80<sup>(2)</sup> | 66871 | I | By trust |
| Common Stock | 2020-11-10 |  | J<sup>(6)</sup> |  | 2500<sup>(2)</sup> | D | 40.006<sup>(2)</sup> | 5763 | D |  |
| Common Stock | 2020-11-10 |  | P<sup>(6)</sup> |  | 2500<sup>(2)</sup> | A | 40.006<sup>(2)</sup> | 69371 | I | By trust |
| Common Stock | 2020-12-10 |  | J<sup>(7)</sup> |  | 658<sup>(2)</sup> | D | $0 | 1442 | I | By son |
| Common Stock | 2021-12-31 |  | G<sup>(8)</sup> |  | 1873<sup>(2)</sup> | D | $0 | 67498 | I | By trust |
| Common Stock | 2021-12-31 |  | G<sup>(8)</sup> |  | 937<sup>(2)</sup> | A | $0 | 2379 | I | By son |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Form 4 originally filed on May 23, 2016 erroneously overstated the Amount of Securities Beneficially Owned by Reporting Person.

(2) The number of securities and price reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.

(3) Form 4 originally filed on April 4, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

(4) Form 4 originally filed on June 7, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

(5) Form 4 originally filed on September 12, 2017 erroneously reported the securities as purchased by Reporting Person rather than by trust.

(6) Form 4 originally filed on November 10, 2020 erroneously reported the securities as purchased by Reporting Person rather than by trust.

(7) Form 4 originally filed on March 19, 2021 erroneously reported a 26,300 share gift as a holding rather than a transaction and further overstated the holdings received by son by 13,150 shares.

(8) This transaction involved a gift of securities by the Reporting Person to his sons, one of which is economically dependent on the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares held by his independent son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his independent son's shares for purposes of Section 16 or for any other purpose.

**Signature:** /s/ Shane Ward, Attorney-in-Fact  
**Date:** 2026-01-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**